Discrepancy between Results and Abstract Conclusions in Industry- vs Nonindustry-funded Studies Comparing Topical Prostaglandins

American Journal of Ophthalmology

Volumn 147, Issue 1, 2009, Pages

  Alasbali, Tariq ^a,b   Smith, Michael ^a   Geffen, Noa ^a   Trope, Graham E ^a   Flanagan, John G ^a,c   Jin, Yaping ^d   Buys, Yvonne M ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b KING FAISAL UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF WATERLOO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TRAVOPROST;

ARTICLE; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; FUNDING; GLAUCOMA; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION;

EID: 57549083469     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.07.005     Document Type: Article

References (63)

1. Moses III H., and Martin J.B. Academic relationships with industry: a new model for biomedical research. JAMA 285 (2001) 933-935
2. Bekelman J.E., Li Y., and Gross C.P. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289 (2003) 454-465
3. Buchkowsky S.S., and Jewesson P.J. Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 38 (2004) 579-585
4. Patsopoulos N.A., Ioannidis J., and Analatos A. Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ 332 (2006) 1061-1064
5. Davidson R.A. Source of funding and outcome of clinical trials. J Gen Intern Med 1 (1986) 155-158
6. Rochon P.A., Gurwitz J.H., Simms R.W., et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 154 (1994) 157-163
7. Cho M.K., and Bero L.A. The quality of drug studies published in symposium proceedings. Ann Intern Med 124 (1996) 485-489
8. Friedberg M., Saffran B., Stinson T.J., Nelson W., and Bennett C.L. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282 (1999) 1453-1457
9. Djulbegovic B., Lacevic M., Cantor A., et al. The uncertainty principle and industry-sponsored research. Lancet 356 (2000) 635-638
10. Clifford T.J., Barrowman N.J., and Moher D. Funding source, trial outcome and reporting quality: are they related?. Results of a pilot study. BMC Health Services Res 2 (2002) 18
11. Kjaergard L.L., and Als-Nielsen B. Association between competing interests and author's conclusions: epidemiological study of randomized clinical trials published in the BMJ. BMJ 325 (2002) 249-253
12. Baker C.B., Johnsrud M.T., Crismon M.L., Rosenheck R.A., and Woods S.W. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 183 (2003) 498-506
13. Lexchin J., Bero L.A., Djulbegovic B., and Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326 (2003) 1167-1170
14. Leopold S.S., Warme W.J., Fritz Braunlich E., and Shott S. Association between funding source and study outcome in orthopaedic research. Clin Orthop 415 (2003) 293-301
15. Als-Nielsen B., Chen W., Gluud C., and Kjaergard L.L. Association of funding and conclusions in randomized drug trials. A reflection of treatment effect or adverse events?. JAMA 290 (2003) 921-928
16. Bhandari M., Busse J.W., Jackowski D., et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Can Med Assoc J 170 (2004) 481-483
17. Finucane T.E., and Boult C.E. Association of funding and findings of pharmaceutical research at a meeting of a medical professional society. Am J Med 117 (2004) 842-845
18. Shah R.V., Albert T.J., Bruegel-Sanchez V., Vaccaro A.R., Hilibrand A.S., and Grauer J.N. Industry support and correlation to study outcome for papers published in Spine. Spine 30 (2005) 1099-1104
19. Perlis R.H., Perlis C.S., Wu Y., Hwang C., Joseph M., and Nierenberg A.A. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 162 (2005) 1957-1960
20. Yank V., Rennie D., and Bero L.A. Financial ties and concordance between results and conclusions in meta-analysis: retrospective cohort study. BMJ 335 (2007) 1202-1205
21. Easterbrook P.J., Berlin J.A., Gopalan R., and Matthews D.R. Publication bias in clinical research. Lancet 337 (1991) 867-872
22. Dickerson K., Min Y.-I., and Meinert C.L. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 267 (1992) 374-378
23. Lynch J.R., Cunningham M.R., Warme W.J., Schaad D.C., Wolf F.M., and Leopold S.S. Commercially funded and United States-based research is more likely to be published; good-quality studies with negative outcomes are not. J Bone Joint Surg [Am] 89 (2007) 1010-1018
24. Users' Guides to the Medical Literature. Essentials of Evidence-based Clinical Practice (2001), American Medical Association, Chicago, Illinois
25. Gandolfi S., Simmons S.T., Sturm R., Chen K., and VanDenburgh A.M. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 18 (2001) 110-121
26. Dirks M.S., Noecker R.J., Earl M., Roh S., Silverstein S.M., and Williams R.D. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther 23 (2006) 385-393
27. Simmons S.T., Dirks M.S., and Noecker R.J. Bimatoprost versus latanoprost in lowering pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Adv Ther 21 (2004) 247-262
28. DuBiner H., Cooke D., Dirks M., Stewart W., VanDenburgh A., and Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 45 (2001) S353-S360
29. Choplin N., Bernestein P., Batoosingh A., and Whitcup S.M. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol 49 (2003) S19-S25
30. Noecker R., Dirks M., Choplin N., et al. A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 135 (2003) 921-922
31. Noecker R.J., Earl M.L., Mundorf T., Peace J., and Williams R.D. Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther 20 (2003) 121-128
32. Cantor L.B., WuDunn D., Cortes A., Hoop J., and Knotts S. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Surv Ophthalmol 49 (2004) S12-S18
33. Walters T.R., DuBiner H.B., Carpenter S.P., Khan B., and VanDenburgh A.M. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 49 (2004) S26-S35
34. Walt J., and Lee J. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv Ophthalmol 49 (2004) 36-44
35. Holmstrom S., Buchholz P., Walt J., Wickstrøm J., and Aagren M. Analytic review of bimatoprost, latanoprost and travoprost in primary open-angle glaucoma. Curr Med Res Opin 21 (2005) 1875-1883
36. Law S.K., Song B.J., Fang E., and Caprioli J. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization. Ophthalmology 112 (2005) 2123-2130
37. Zeitz O., Matthiessen E., Reuss J., et al. Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide. BMC Ophthalmology 5 (2005) 6
38. Cantor L.B., Hoop J., Morgan L., Wudunn D., and Catoira Y. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 90 (2006) 1370-1373
39. Fiscella R., and Walt J. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension. Drugs Aging 23 (2006) 39-47
40. Noecker R.J., Earl M.L., Mundorf T.K., Silverstein S.M., and Phillips M.P. Comparing bimatoprost and travoprost in black Americans. Curr Med Res Opin 22 (2006) 2175-2180
41. Konstas A., Hollo G., Irkec M., et al. Diurnal IOP control with bimatoprost vs latanoprost in exfoliative glaucoma: a crossover observer-masked three-center study. Br J Ophthalmol 91 (2007) 757-760
42. Martinez A., and Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin 23 (2007) 1025-1032
43. Netland P.A., Robertson S.M., Sullivan E.K., et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132 (2001) 472-484
44. Halpern M.T., Covert D.W., and Robin A.L. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects. Trans Am Ophthalmol Soc 100 (2002) 109-118
45. Cardascia N., Vetrugno M., Trabucco T., Cantatore F., and Sborgia C. Effect of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: a 180-day, randomized, double-masked comparison with latanoprost eye drops in patients with open-angle glaucoma. Curr Ther Res 64 (2003) 389-400
46. Nordmann J.P., Lepen C., Lilliu H., and Berdeaux G. Estimating the long-term visual field consequences of average daily intraocular pressure and variance: a clinical trial comparing timolol, latanoprost, and travoprost. Clin Drug Invest 23 (2003) 431-438
47. DuBiner H.B., Sircy M.D., Landry T., et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 26 (2004) 84-91
48. Denis P., Launois R., Devaux M., and Berdeaux G. Comparison of diurnal intraocular pressure control by latanoprost versus travoprost: results of an observational survey. Clin Drug Invest 26 (2006) 703-714
49. García-Feijoo J., Martínez-de-la-Casa J.M., Castillo A., Méndez C., Fernández-Vidal A., and García-Sánchez J. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin 22 (2006) 1689-1697
50. Franks W.A., Renard J.P., Cunliffe I.A., and Rojanapongpun P. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ther 28 (2006) 332-339
51. Schmier J., Halpern M., Covert D., and Robin A. Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression. Curr Med Res Opin 22 (2006) 1737-1743
52. Denis P., Lafuma A., Khoshnood B., Mimaud V., and Berdeaux G. A meta-analysis of topical prostaglandin analogues intraocular pressure lowering in glaucoma therapy. Curr Med Res Opin 23 (2007) 601-608
53. Parrisk R.K., Palmberg P., and Sheu W.P. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135 (2003) 688-703
54. Inan U., Ermis S., Orman A., et al. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topica travoprost, bimatoprost, brimonidine, and betaxolol. J Ocul Pharmacol Ther 20 (2004) 293-310
55. Konstas A.G., Katsimbris J.M., Lallos N., Boukaras G.P., Jenkins J.N., and Steward W.C. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 112 (2005) 262-266
56. Arici M.K., Erdogan H., Toker I., Vural A., and Topalkara A. The effect of latanoprost, bimatoprost, and travoprost on intraocular pressure after cataract surgery. J Ocul Pharmacol Ther 22 (2006) 34-40
57. Chen M.J., Chen Y.C., Chou C.K., and Hsu W.M. Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma. J Ocul Pharmacol Ther 22 (2006) 449-454
58. Li N., Chen X.M., Zhou Y., Wei M.L., and Yao X. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol 34 (2006) 755-764
59. Orzalesi N., Rossetti L., Bottoli A., and Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 113 (2006) 239-246
60. Konstas A.G., Kozobolis V.P., Katsimpris I.E., et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology 114 (2007) 653-657
61. Hepsen I.F., and Ozkaya E. 24-hours IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye 21 (2007) 453-458
62. Parmaksiz S., Yüksel N., Karabas V.L., Ozkan B., Demirci G., and Caglar Y. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol 16 (2006) 73-80
63. Van der Valk R., Webers C.A., Schouten J.S., Zeegers M.P., Hendrikse F., and Prins M.H. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112 (2005) 1177-1185